Over the past month AcelRx’s (ACRX) stock has experienced high volatility due to a looming FDA decision on the company’s lead drug DSUVIA. Typically a pending FDA approval decision generates a spike in volatility for the candidate’s stock; but ACRX’s story is not typical. The briefing document debacle followed by a positive FDA advisory committee vote provided plenty of opportunities for traders and investors to catch an entry point. However, I didn’t forecast the political incursion that transpired October 18th. News quickly spread that the advisory committee’s chairman, Dr. Raeford Brown